Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acted for Carnegie and Kempen & Co in connection with BioInvent’s private placement of new shares
Mandate

Vinge acted for Carnegie and Kempen & Co in connection with BioInvent’s private placement of new shares

June 09, 2011

BioInvent International AB (publ) (NASDAQ OMX Stockholm) has completed a private placement of new shares with international institutional investors and qualified investors in Sweden through an accelerated bookbuilding procedure. Carnegie Investment Bank and Kempen & Co acted as Joint Global Co-ordinators and Joint Bookrunners.

Vinge and Latham & Watkins were legal advisors to the bookrunners. The Vinge team was headed by capital markets partner Erik Sjöman.

Related

Vinge is advising Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135 million before deduction of transaction costs.
December 03, 2024

Vinge has represented Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB

 Vinge has represented the leading infrastructure group Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB from Vestum. These companies are engaged in contracting activities within the construction sector. The total purchase price for the shares amounts to 747 MSEK. All key executives in the companies will become shareholders in Eleda.
December 02, 2024

Vinge has advised Fortum in connection with the divestment of its recycling and waste business

 Vinge, alongside among others Castrén & Snellman, has advised Fortum in connection with the divestment of its recycling and waste business to Summa Equity through its portfolio company NG Group. The debt free purchase price is approximately EUR 800 million.
December 02, 2024